Literature DB >> 19482514

Non-invasive molecular imaging of prostate cancer lymph node metastasis.

Frédéric Pouliot1, Mai Johnson, Lily Wu.   

Abstract

Imaging in medicine has been classically based on the anatomical description of organs. In the past 15 years, new imaging techniques based on gene expression that characterize a pathological process have been developed. Molecular imaging is the use of such molecules to image cell-specific characteristics. Here, we review recent advances in molecular imaging, taking as our prime example lymph node (LN) metastasis in prostate cancer. We describe the new techniques and compare their accuracy in detecting LN metastasis in prostate cancer. We also present new molecular strategies for improving tumor detection using adenoviruses, molecular promoters and amplification systems. Finally, we present the concept of 'in vivo pathology', which envisages using molecular imaging to accurately localize metastatic lesions based on the molecular signature of the disease.

Entities:  

Mesh:

Year:  2009        PMID: 19482514      PMCID: PMC2798142          DOI: 10.1016/j.molmed.2009.04.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  62 in total

1.  MR evaluation of normal retroperitoneal and pelvic lymph nodes.

Authors:  Sisa Grubnic; Sarah J Vinnicombe; Andrew R Norman; Janet E Husband
Journal:  Clin Radiol       Date:  2002-03       Impact factor: 2.350

2.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

3.  FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume.

Authors:  J D Wagner; D S Schauwecker; D Davidson; S Wenck; S H Jung; G Hutchins
Journal:  J Surg Oncol       Date:  2001-08       Impact factor: 3.454

4.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Authors:  I J Liu; M B Zafar; Y H Lai; G M Segall; M K Terris
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

5.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters.

Authors:  M Iyer; L Wu; M Carey; Y Wang; A Smallwood; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 6.  Positron emission tomography for staging and management of malignant melanoma.

Authors:  R S Prichard; A D K Hill; S J Skehan; N J O'Higgins
Journal:  Br J Surg       Date:  2002-04       Impact factor: 6.939

7.  Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging.

Authors:  Jason Y Adams; Mai Johnson; Makoto Sato; Frank Berger; Sanjiv S Gambhir; Michael Carey; M Luisa Iruela-Arispe; Lily Wu
Journal:  Nat Med       Date:  2002-07-22       Impact factor: 53.440

8.  Detection of a non-Hodgkin's lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma.

Authors:  Italo Zanzi; Richard Stark
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

9.  Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.

Authors:  Jörg Kotzerke; Björn G Volkmer; Bernd Neumaier; Jürgen E Gschwend; Richard E Hautmann; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-27       Impact factor: 9.236

Review 10.  Imaging in lung cancer: positron emission tomography scan.

Authors:  J F Vansteenkiste
Journal:  Eur Respir J Suppl       Date:  2002-02
View more
  9 in total

Review 1.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

2.  In vivo imaging of intraprostatic-specific gene transcription by PET.

Authors:  Frédéric Pouliot; Breanne D W Karanikolas; Mai Johnson; Makoto Sato; Saul J Priceman; David Stout; Joanne Sohn; Nagichettiar Satyamurthy; Jean B deKernion; Lily Wu
Journal:  J Nucl Med       Date:  2011-04-15       Impact factor: 10.057

3.  A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.

Authors:  Frédéric Pouliot; Makoto Sato; Ziyue Karen Jiang; Steve Huyn; Breanne Dw Karanikolas; Lily Wu
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

4.  Oxidative stress and DNA methylation in prostate cancer.

Authors:  Krishna Vanaja Donkena; Charles Y F Young; Donald J Tindall
Journal:  Obstet Gynecol Int       Date:  2010-06-29

5.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

6.  FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Authors:  Jean-Mathieu Beauregard; Annie-Claude Blouin; Vincent Fradet; André Caron; Yves Fradet; Claude Lemay; Louis Lacombe; Thierry Dujardin; Rabi Tiguert; Goran Rimac; Frédérick Bouchard; Frédéric Pouliot
Journal:  Cancer Imaging       Date:  2015-03-03       Impact factor: 3.909

7.  SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization.

Authors:  Jiangchun Wu; Yong Wu; Qinhao Guo; Xiaohua Wu; Jun Zhu; Xingzhu Ju; Siyu Chen; Simin Wang
Journal:  J Transl Med       Date:  2022-08-30       Impact factor: 8.440

8.  A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.

Authors:  Bertrand Neveu; Pallavi Jain; Bernard Têtu; Lily Wu; Yves Fradet; Frédéric Pouliot
Journal:  Oncotarget       Date:  2016-01-12

9.  Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Authors:  Pallavi Jain; Bertrand Neveu; Lauriane Velot; Lily Wu; Yves Fradet; Frédéric Pouliot
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.